{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:16:48Z","timestamp":1787930208244,"version":"build-2784847793"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00347-026-02511-y","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:06:50Z","timestamp":1787576810000},"page":"745-756","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Botulinumtoxin\u00a0A in der ophthalmologischen Praxis: therapeutische und \u00e4sthetische Anwendungen","Botulinum toxin\u00a0A in the ophthalmological practice: therapeutic and esthetic applications"],"prefix":"10.1007","volume":"123","author":[{"given":"Ines","family":"Lanzl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Abdelwahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"2511_CR1","doi-asserted-by":"crossref","unstructured":"Carruthers, A. and J.\u00a0Carruthers (2001) Botulinum toxin type\u00a0A:\u00a0history and current cosmetic use in the upper face. Seminars in Cutaneous Medicine and Surgery p.\u00a071\u201384.","DOI":"10.1053\/sder.2001.25138"},{"key":"2511_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrmicro3295","volume":"12","author":"O Rossetto","year":"2014","unstructured":"Rossetto\u00a0O, Pirazzini\u00a0M, Montecucco\u00a0C (2014) Botulinum neurotoxins: genetic, structural and mechanistic insights. Nature Reviews Microbiology 12:535\u2013549","journal-title":"Nature Reviews Microbiology"},{"key":"2511_CR3","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1002\/mds.20022","volume":"19","author":"D Dressler","year":"2004","unstructured":"Dressler\u00a0D (2004) Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Movement Disorders 19:S92\u2013S100","journal-title":"Movement Disorders"},{"key":"2511_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1468-1331.2006.01439.x","volume":"13","author":"D Dressler","year":"2006","unstructured":"Dressler\u00a0D, Hallett\u00a0M (2006) Immunological aspects of Botox, Dysport and Myobloc\/NeuroBloc. European Journal of Neurology 13:11\u201315","journal-title":"European Journal of Neurology"},{"key":"2511_CR5","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1002\/mds.20024","volume":"19","author":"J Jankovic","year":"2004","unstructured":"Jankovic\u00a0J (2004) Treatment of cervical dystonia with botulinum toxin. Movement Disorders 19:S109\u2013S115","journal-title":"Movement Disorders"},{"key":"2511_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1468-1331.2009.02879.x","volume":"16","author":"J Frevert","year":"2009","unstructured":"Frevert\u00a0J (2009) Xeomin: an innovative new botulinum toxin type\u00a0A. European Journal of Neurology 16:11\u201313","journal-title":"European Journal of Neurology"},{"key":"2511_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/toxins8030065","volume":"8","author":"F Scaglione","year":"2016","unstructured":"Scaglione\u00a0F (2016) Conversion ratio between Botox, Dysport, and Xeomin in clinical practice. Toxins 8:65","journal-title":"Toxins"},{"key":"2511_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/toxins16060266","volume":"16","author":"MF Brin","year":"2024","unstructured":"Brin\u00a0MF et\u00a0al (2024) Update on non-interchangeability of botulinum neurotoxin products. Toxins 16:266","journal-title":"Toxins"},{"key":"2511_CR9","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","volume":"86","author":"DM Simpson","year":"2016","unstructured":"Simpson\u00a0DM et\u00a0al (2016) Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache [RETIRED]: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 86:1818\u20131826","journal-title":"Neurology"},{"key":"2511_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1468-1331.2006.01438.x","volume":"13","author":"RL Rosales","year":"2006","unstructured":"Rosales\u00a0RL, Bigalke\u00a0H, Dressler\u00a0D (2006) Pharmacology of botulinum toxin: differences between type A preparations. European Journal of Neurology 13:2\u201310","journal-title":"European Journal of Neurology"},{"key":"2511_CR11","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1055\/s-0042-122339","volume":"235","author":"B Wabbels","year":"2018","unstructured":"Wabbels\u00a0B (2018) Botulinumtoxintherapie \u2013 neue Entwicklungen in der Augenheilkunde. Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde 235:721\u2013724","journal-title":"Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"},{"key":"2511_CR12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00702-011-0762-y","volume":"119","author":"B Wabbels","year":"2012","unstructured":"Wabbels\u00a0B, Roggenk\u00e4mper\u00a0P (2012) Botulinum toxin in hemifacial spasm: the challenge to assess the effect of treatment. Journal of Neural Transmission 119:963\u2013980","journal-title":"Journal of Neural Transmission"},{"key":"2511_CR13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s00347-016-0302-0","volume":"113","author":"B Wabbels","year":"2016","unstructured":"Wabbels\u00a0B (2016) Zum Einsatz von Botulinumtoxin in der Strabologie. Der Ophthalmologe 113:544\u2013549","journal-title":"Der Ophthalmologe"},{"key":"2511_CR14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00347-007-1611-0","volume":"104","author":"RL Mert\u00e9","year":"2007","unstructured":"Mert\u00e9\u00a0RL, Lanzl\u00a0IM (2007) Botulinumtoxin-Injektionen zur Erzeugung einer Ptosis. Der Ophthalmologe 104:767\u2013770","journal-title":"Der Ophthalmologe"},{"key":"2511_CR15","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00347-007-1592-z","volume":"104","author":"B Wabbels","year":"2007","unstructured":"Wabbels\u00a0B, F\u00f6rl\u00a0M (2007) Botulinumtoxin bei \u00dcberfunktion der Tr\u00e4nendr\u00fcse, spastischem Entropium und Oberlidretraktion bei endokriner Orbitopathie. Der Ophthalmologe 104:771\u2013776","journal-title":"Der Ophthalmologe"},{"key":"2511_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1055\/s-0034-1396142","volume":"232","author":"I Lanzl","year":"2015","unstructured":"Lanzl\u00a0I, Mert\u00e9\u00a0RL, Poimenidou\u00a0M (2015) Botulinumtoxin-Injektionen bei senilem Entropium. Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde 232:37\u201339","journal-title":"Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"},{"issue":"1","key":"2511_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1524-4725.1992.tb03295.x","volume":"18","author":"JD Carruthers","year":"1992","unstructured":"Carruthers\u00a0JD, Carruthers\u00a0JA (1992) Treatment of glabellar frown lines with C. botulinum\u2011A exotoxin. The Journal of dermatologic surgery and oncology 18(1):17\u201321","journal-title":"The Journal of dermatologic surgery and oncology"},{"issue":"2","key":"2511_CR18","doi-asserted-by":"publisher","first-page":"265e","DOI":"10.1097\/PRS.0000000000003544","volume":"140","author":"M De Maio","year":"2017","unstructured":"De Maio\u00a0M et\u00a0al (2017) Facial assessment and injection guide for botulinum toxin and injectable hyaluronic acid fillers: focus on the upper face. Plastic and reconstructive surgery 140(2):265e\u2013276e","journal-title":"Plastic and reconstructive surgery"},{"issue":"5","key":"2511_CR19","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/DSS.0000000000000754","volume":"42","author":"J Carruthers","year":"2016","unstructured":"Carruthers\u00a0J et\u00a0al (2016) Consensus recommendations for combined aesthetic interventions in the face using botulinum toxin, fillers, and energy-based devices. Dermatologic surgery 42(5):586\u2013597","journal-title":"Dermatologic surgery"},{"issue":"5","key":"2511_CR20","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1097\/PRS.0000000000002119","volume":"137","author":"H Sundaram","year":"2016","unstructured":"Sundaram\u00a0H et\u00a0al (2016) Global aesthetics consensus: hyaluronic acid fillers and botulinum toxin type\u00a0A\u2014recommendations for combined treatment and optimizing outcomes in diverse patient populations. Plastic and reconstructive surgery 137(5):1410\u20131423","journal-title":"Plastic and reconstructive surgery"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02511-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-026-02511-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02511-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:18:12Z","timestamp":1787926692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-026-02511-y"}},"subtitle":["Indikationen, Voraussetzungen und Durchf\u00fchrung","Indications, prerequisites and procedure"],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2511"],"URL":"https:\/\/doi.org\/10.1007\/s00347-026-02511-y","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"I.\u00a0Lanzl\n                      : A. Finanzielle Interessen: I. Lanzl gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B. Nichtfinanzielle Interessen: Fach\u00e4rztin Klinik und Poliklinik f\u00fcr Augenheilkunde, TUM Klinikum Rechts der Isar; \u00c4rztin und Inhaberin der Chiemsee Augen-Tagesklinik, Prien am Chiemsee, Deutschland; \u00c4rztin und Gesch\u00e4ftsf\u00fchrerin bei Clarity Aesthetik, M\u00fcnchen.\n                      A. Assaf\n                      : A. Finanzielle Interessen: A. Assaf gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B. Nichtfinanzielle Interessen: Assistenzarzt Klinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Ulm; Arzt und Gesch\u00e4ftsf\u00fchrer bei Clarity Aesthetik, M\u00fcnchen.\n                      R. Abdelwahed\n                      : A. Finanzielle Interessen: R. Abdelwahed gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B. Nichtfinanzielle Interessen: \u00c4rztin bei Clarity Aesthetik, M\u00fcnchen.\n                      C. Miller\n                      : A. Finanzielle Interessen: C. Miller gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B. Nichtfinanzielle Interessen: Ober\u00e4rztin an der Klinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Ulm.","order":2,"name":"Ethics","label":"Autorinnen und Autoren","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":3,"name":"Ethics","label":"Wissenschaftliche Leitung","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":4,"name":"Ethics","label":"Der Verlag","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}